Oral immunotherapy with type v collagen in idiopathic pulmonary fibrosis

European Respiratory Journal

Volumn 45, Issue 5, 2015, Pages 1393-1402

  Wilkes, David S ^a,b   Chew, Terrence ^a   Flaherty, Kevin R ^c   Frye, Sarah ^a   Gibson, Kevin F ^d   Kaminski, Naftali ^e   Klemsz, Michael J ^a,b   Lange, Wade ^a   Noth, Imre ^f   Rothhaar, Katia ^a  

^a ImmuneWorks Inc ^*  (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; COLLAGEN ANTIBODY; GELATINASE B; IMMUNOGLOBULIN G ANTIBODY; MATRILYSIN; BIOLOGICAL MARKER; COLLAGEN TYPE 5; COMPLEMENT COMPONENT C1Q; MMP7 PROTEIN, HUMAN; SERUM ALBUMIN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EDEMA; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOMODULATION; KIDNEY DISEASE; LUNG FUNCTION; LUNG INFECTION; MALE; MULTICENTER STUDY; MYALGIA; ORAL IMMUNOTHERAPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; SKIN DISEASE; VASCULAR DISEASE; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG; LUNG FUNCTION TEST; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT SAFETY; PROCEDURES; VITAL CAPACITY;

ADMINISTRATION, ORAL; AGED; BIOMARKERS; COHORT STUDIES; COLLAGEN TYPE V; COMPLEMENT C1Q; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOTHERAPY; LUNG; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; PATIENT SAFETY; RESPIRATORY FUNCTION TESTS; SERUM ALBUMIN; VITAL CAPACITY;

EID: 84928981380     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00105314     Document Type: Article

References (33)

1. Rafii R, Juarez MM, Albertson TE, et al. A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis 2013; 5: 48-73.
2. Adamali HI, Maher TM. Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther 2012; 6: 261-272.
3. Wick G, Grundtman C, Mayerl C, et al. The immunology of fibrosis. Ann Rev Immunol 2013; 31: 107-135.
4. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011; 208: 1339-1350.
5. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat Med 2012; 18: 1028-1040.
6. Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol 2011; 163: 141-172.
7. Zhang Y, Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Curr Op Pulm Med 2012; 18: 441-446.
8. Kahloon RA, Xue J, Bhargava A, et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 2013; 187: 768-775.
9. Feghali-Bostwick CA, Tsai CG, Valentine VG, et al. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol 2007; 179: 2592-1599.
10. Vittal R, Mickler EA, Fisher AJ, et al. Type V collagen induced tolerance suppresses collagen deposition, TGF-beta and associated transcripts in pulmonary fibrosis. PLoS One 2013; 8: E76451.
11. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007; 117: 3498-3506.
12. Parra ER, Teodoro WR, Velosa AP, et al. Interstitial and vascular type V collagen morphologic disorganization in usual interstitial pneumonia. J Histochem Cytochem 2006; 54: 1315-1325.
13. Sumpter TL, Wilkes DS. Role of autoimmunity in organ allograft rejection: A focus on immunity to type V collagen in the pathogenesis of lung transplant rejection. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1129-L1139.
14. Fukami N, Ramachandran S, Saini D, et al. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol 2009; 182: 309-318.
15. Yasufuku K, Heidler KM, O'Donnell PW, et al. Oral tolerance induction by type V collagen downregulates lung allograft rejection. Am J Respir Cell Mol Biol 2001; 25: 26-34.
16. Yasufuku K, Heidler KM, Woods KA, et al. Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation 2002; 73: 500-505.
17. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
18. Iwata T, Philipovskiy A, Fisher AJ, et al. Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol 2008; 181: 5738-5747.
19. Shankar G, Devanarayan V, Amaravadi L, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008; 48: 1267-1281.
20. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830-836.
21. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185: 67-76.
22. Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res 2012; 159: 218-227.
23. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008; 5: E93.
24. Alhamad EH, Al-Kassimi FA, Alboukai AA, et al. Comparison of three groups of patients with usual interstitial pneumonia. Respir Med 2012; 106: 1575-1585.
25. Todd NW, Luzina IG, Atamas SP. Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair 2012; 5: 11.
26. Kaunisto J, Salomaa ER, Hodgson U, et al. Idiopathic pulmonary fibrosis-a systematic review on methodology for the collection of epidemiological data. BMC Pulm Med 2013; 13: 53.
27. Bobadilla JL, Love RB, Jankowska-Gan E, et al. Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med 2008; 177: 660-608.
28. Duncan AR, Winter G. The binding site for C1q on IgG. Nature 1988; 332: 738-740.
29. Weiner HL, da Cunha AP, Quintana F, et al. Oral tolerance. Immunol Rev 2011; 241: 241-259.
30. Wang X, Sherman A, Liao G, et al. Mechanism of oral tolerance induction to therapeutic proteins. Adv Drug Deliv Rev 2013; 65: 759-773.
31. Scadding GW, Shamji MH, Jacobson MR, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40: 598-606.
32. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011; 377: 1760-1769.
33. FDA Briefing, PADAC, pg 72, Table 15. 2010. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM203081.pdf.